

PF 42(5) Table of Contents

Publish date: August 31, 2016

PROPOSED IRA

[Proposed Interim Revision Announcements](#)

USP MONOGRAPHS

[Anastrozole Tablets \(1-Mar-2017\)](#)

IN-PROCESS REVISION

[In-Process Revision](#)

GENERAL CHAPTERS

[<161> Medical Devices - Bacterial Endotoxin and Pyrogen Tests \(USP40-NF35 2S\)](#)

[<197> Spectrophotometric Identification Tests \(USP40-NF35 2S\)](#)

[<503> Acetic Acid In Peptides \(USP40-NF35 2S\)](#)

[<503.1> Trifluoroacetic Acid \(TFA\) in Peptides \(USP40-NF35 2S\)](#)

[<509> Residual DNA Testing \[NEW\] \(USP40-NF35 2S\)](#)

[<1062> Tablet Compression Characterization \[NEW\] \(USP40-NF35 2S\)](#)

[<1080> Bulk Pharmaceutical Excipients - Certificate of Analysis \(USP40-NF35 2S\)](#)

[<1210> Statistical Tools for Procedure Validation \[NEW\] \(USP40-NF35 2S\)](#)

[<1211> Sterilization and Sterility Assurance of Compendial Articles \(USP40-NF35 2S\)](#)

[<1229.14> Sterilization Cycle Development \[NEW\] \(USP40-NF35 2S\)](#)

[<1229.15> Sterilizing Filtration of Gases \[NEW\] \(USP40-NF35 2S\)](#)

REAGENTS, INDICATORS, AND SOLUTIONS

Reagent Specifications

[Dihydroxybenzaldehyde \[NEW\] \(USP40-NF35 2S\)](#)

[Dihydroxyphenylacetone \[NEW\] \(USP40-NF35 2S\)](#)

[7,8-Dihydrofolic Acid \[NEW\] \(USP40-NF35 2S\)](#)

[Hydroxypropyl-\[BETA\]-cyclodextrin \(USP40-NF35 2S\)](#)

[Mercurous Nitrate Dihydrate \(USP40-NF35 2S\)](#)

[Methyl Isobutyrate \[NEW\] \(USP40-NF35 2S\)](#)

[Nickel Sulfate \(USP40-NF35 2S\)](#)

[n-Octane \[NEW\] \(USP40-NF35 2S\)](#)

[Tetraethylammonium Chloride \[NEW\] \(USP40-NF35 2S\)](#)

[Triazolam \[NEW\] \(USP40-NF35 2S\)](#)

Indicators

[Phenolphthalein \(USP40-NF35 2S\)](#)

Test Solutions

[0.008 M Acetic Acid TS \[NEW\] \(USP40-NF35 2S\)](#)

[0.3 N Acetic Acid TS \[NEW\] \(USP40-NF35 2S\)](#)

[0.08 N Hydrochloric Acid TS \[NEW\] \(USP40-NF35 2S\)](#)

[0.75 M Phosphoric Acid TS \[NEW\] \(USP40-NF35 2S\)](#)

REFERENCE TABLES

Containers for Dispensing Capsules and Tablets

[Containers for Dispensing Capsules and Tablets \[NEW\] \(USP40-NF35 2S\)](#)

Description and Relative Solubility of USP and NF Articles

[Description and Relative Solubility of USP and NF Articles \(USP40-NF35 2S\)](#)

[Description and Solubility - G](#)

[Description and Solubility - M](#)

[Description and Solubility - O](#)

[Description and Solubility - R](#)

USP MONOGRAPHS

[Acetaminophen and Aspirin Tablets \(USP40-NF35 2S\)](#)

[Acetaminophen, Aspirin, and Caffeine Tablets \(USP40-NF35 2S\)](#)

[Anagrelide Capsules \(USP40-NF35 2S\)](#)

[Antipyrine and Benzocaine Otic Solution \(USP40-NF35 2S\)](#)

[Ascorbic Acid Compounded Oral Solution \[NEW\] \(USP40-NF35 2S\)](#)

[Baclofen Tablets \(USP40-NF35 2S\)](#)

[Betamethasone Acetate \(USP40-NF35 2S\)](#)

[Betamethasone Dipropionate Topical Aerosol \(USP40-NF35 2S\)](#)

[Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension \(USP40-NF35 2S\)](#)

[Budesonide Delayed-Release Capsules \[NEW\] \(USP40-NF35 2S\)](#)

[Carbidopa and Levodopa Tablets \(USP40-NF35 2S\)](#)

[Cytarabine \(USP40-NF35 2S\)](#)

[Decoquinat Premix \(USP40-NF35 2S\)](#)

[Dexamethasone Sodium Phosphate Compounded Injection \[NEW\] \(USP40-NF35 2S\)](#)

[Divalproex Sodium \(USP40-NF35 2S\)](#)

[Divalproex Sodium Delayed-Release Tablets \(USP40-NF35 2S\)](#)

[Divalproex Sodium Extended-Release Tablets \(USP40-NF35 2S\)](#)

[Docetaxel Injection \(USP40-NF35 2S\)](#)

[Doxycycline for Oral Suspension \(USP40-NF35 2S\)](#)

[Estriol Compounded Vaginal Cream \[NEW\] \(USP40-NF35 2S\)](#)

[Fentanyl Citrate Compounded Injection \[NEW\] \(USP40-NF35 2S\)](#)

[Fentanyl Citrate and Bupivacaine Hydrochloride Compounded Injection \[NEW\] \(USP40-NF35 2S\)](#)

[Fentanyl Citrate and Ropivacaine Hydrochloride Compounded Injection \[NEW\] \(USP40-NF35 2S\)](#)

[Flutamide Capsules \(USP40-NF35 2S\)](#)
[Fluvoxamine Maleate \(USP40-NF35 2S\)](#)
[Fluvoxamine Maleate Tablets \(USP40-NF35 2S\)](#)
[Folic Acid Compounded Oral Solution \[NEW\] \(USP40-NF35 2S\)](#)
[Fondaparinux Sodium \(USP40-NF35 2S\)](#)
[Fondaparinux Sodium Injection \(USP40-NF35 2S\)](#)
[Hydralazine Hydrochloride \(USP40-NF35 2S\)](#)
[Hydralazine Hydrochloride Tablets \(USP40-NF35 2S\)](#)
[Hydrocortisone Injectable Suspension \(USP40-NF35 2S\)](#)
[Hydrocortisone Acetate Injectable Suspension \(USP40-NF35 2S\)](#)
[Hydrocortisone Acetate Ophthalmic Suspension \(USP40-NF35 2S\)](#)
[Indomethacin Capsules \(USP40-NF35 2S\)](#)
[Insulin Aspart \(USP40-NF35 2S\)](#)
[Diluted Isosorbide Dinitrate \(USP40-NF35 2S\)](#)
[Isosorbide Dinitrate Tablets \(USP40-NF35 2S\)](#)
[Leucovorin Calcium \(USP40-NF35 2S\)](#)
[Leucovorin Calcium for Injection \[NEW\] \(USP40-NF35 2S\)](#)
[Lithium Hydroxide \(USP40-NF35 2S\)](#)
[Mefenamic Acid \(USP40-NF35 2S\)](#)
[Mefenamic Acid Capsules \(USP40-NF35 2S\)](#)
[Meropenem \(USP40-NF35 2S\)](#)
[Meropenem for Injection \(USP40-NF35 2S\)](#)
[Methohexital \(USP40-NF35 2S\)](#)
[Methohexital Sodium for Injection \(USP40-NF35 2S\)](#)
[Methylnaltrexone Bromide \[NEW\] \(USP40-NF35 2S\)](#)
[Metoprolol Succinate Extended-Release Tablets \(USP40-NF35 2S\)](#)
[Monensin Premix \(USP40-NF35 2S\)](#)
[Morphine Sulfate Compounded Injection \[NEW\] \(USP40-NF35 2S\)](#)
[Narasin Premix \(USP40-NF35 2S\)](#)
[Nimodipine \(USP40-NF35 2S\)](#)
[Olanzapine and Fluoxetine Capsules \(USP40-NF35 2S\)](#)
[Ondansetron Compounded Topical Gel \[NEW\] \(USP40-NF35 2S\)](#)
[Oxiconazole Nitrate \[NEW\] \(USP40-NF35 2S\)](#)
[Pentazocine \(USP40-NF35 2S\)](#)
[Pentazocine Injection \(USP40-NF35 2S\)](#)
[Phenytoin Chewable Tablets \(USP40-NF35 2S\)](#)
[Potassium Phosphates Compounded Injection \[NEW\] \(USP40-NF35 2S\)](#)
[Protriptyline Hydrochloride Tablets \(USP40-NF35 2S\)](#)
[Raltegravir Tablets \[NEW\] \(USP40-NF35 2S\)](#)
[Raltegravir Chewable Tablets \[NEW\] \(USP40-NF35 2S\)](#)
[Raltegravir Potassium \[NEW\] \(USP40-NF35 2S\)](#)
[Sodium Bicarbonate Compounded Injection \[NEW\] \(USP40-NF35 2S\)](#)
[Sodium Phosphates Compounded Injection \[NEW\] \(USP40-NF35 2S\)](#)
[Silver Sulfadiazine \(USP40-NF35 2S\)](#)

[Teriparatide \(USP40-NF35 2S\)](#)
[Teriparatide Injection \(USP40-NF35 2S\)](#)
[Trandolapril Tablets \(USP40-NF35 2S\)](#)
[Trihexyphenidyl Hydrochloride Oral Solution \(USP40-NF35 2S\)](#)

DIETARY SUPPLEMENT MONOGRAPHS

[Tangerine Peel \[NEW\] \(USP40-NF35 2S\)](#)
[Tangerine Peel Powder \[NEW\] \(USP40-NF35 2S\)](#)
[Tangerine Peel Dry Extract \[NEW\] \(USP40-NF35 2S\)](#)

EXCIPIENTS

USP and NF Excipients, Listed By Category (USP40-NF35 2S)

[Briefing](#)
[Introduction](#)
[Coating Agent](#)
[Diluent](#)
[Emulsifying Agent](#)
[Film-Forming Agent](#)
[Lubricant](#)
[Vehicle \(solid carrier\)](#)
[Wet Binder](#)

NF MONOGRAPHS

[Almond Oil \(USP40-NF35 2S\)](#)
[Aluminum Monostearate \(USP40-NF35 2S\)](#)
[Canola Oil \(USP40-NF35 2S\)](#)
[Cetyl Esters Wax \(USP40-NF35 2S\)](#)
[Corn Oil \(USP40-NF35 2S\)](#)
[Cottonseed Oil \(USP40-NF35 2S\)](#)
[Dichlorodifluoromethane \(USP40-NF35 2S\)](#)
[Dichlorotetrafluoroethane \(USP40-NF35 2S\)](#)
[Ethyl Acetate \(USP40-NF35 2S\)](#)
[Glyceryl Tricaprylate \[NEW\] \(USP40-NF35 2S\)](#)
[Myristic Acid \(USP40-NF35 2S\)](#)
[Peanut Oil \(USP40-NF35 2S\)](#)
[Polyoxyl 40 Hydrogenated Castor Oil \(USP40-NF35 2S\)](#)
[Sodium Hydroxide \(USP40-NF35 2S\)](#)
[Sodium Lauryl Sulfate \(USP40-NF35 2S\)](#)

STAGE 4 HARMONIZATION

[Stage 4 Harmonization](#)

USP MONOGRAPHS

[Hypromellose](#)
[Methylcellulose](#)

STIMULI TO THE REVISION PROCESS

[Stimuli to The Revision Process](#)

[Analytical Control Strategy](#)

[Analytical Target Profile: Structure and Application Throughout The Analytical Lifecycle](#)

[Applying The USP <905> Content Uniformity Zero Tolerance Criterion to Large Sample Sizes](#)

[Responses to Stimuli Article, "Medicines Marketed Under the Food and Drug Administration](#)

[Over-The-Counter Drug Monograph System Regulations: Strategy for Developing Compendial](#)

[Quality Standards"](#)

[USP Responses to Comments On Stimuli Article Proposed New USP General Information](#)

[Chapter. "Tablet Compression Characterization <1062>"](#)

